172 related articles for article (PubMed ID: 19826403)
1. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Chawla SP; Chua VS; Fernandez L; Quon D; Blackwelder WC; Gordon EM; Hall FL
Mol Ther; 2010 Feb; 18(2):435-41. PubMed ID: 19826403
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
Chawla SP; Chua VS; Fernandez L; Quon D; Saralou A; Blackwelder WC; Hall FL; Gordon EM
Mol Ther; 2009 Sep; 17(9):1651-7. PubMed ID: 19532136
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Galanis E; Carlson SK; Foster NR; Lowe V; Quevedo F; McWilliams RR; Grothey A; Jatoi A; Alberts SR; Rubin J
Mol Ther; 2008 May; 16(5):979-84. PubMed ID: 18388964
[TBL] [Abstract][Full Text] [Related]
4. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
5. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.
Chawla SP; Bruckner H; Morse MA; Assudani N; Hall FL; Gordon EM
Mol Ther Oncolytics; 2019 Mar; 12():56-67. PubMed ID: 30705966
[TBL] [Abstract][Full Text] [Related]
6. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.
Karavasilis V; Samantas E; Koliou GA; Kalogera-Fountzila A; Pentheroudakis G; Varthalitis I; Linardou H; Rallis G; Skondra M; Papadopoulos G; Papatsibas G; Sgouros J; Goudopoulou A; Kalogeras KT; Dervenis C; Pectasides D; Fountzilas G
Target Oncol; 2018 Dec; 13(6):715-724. PubMed ID: 30488350
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
Melnik MK; Webb CP; Richardson PJ; Luttenton CR; Campbell AD; Monroe TJ; O'Rourke TJ; Yost KJ; Szczepanek CM; Bassett MR; Truszkowski KJ; Stein P; Van Brocklin MW; Davis AT; Bedolla G; Vande Woude GF; Koo HM
Mol Cancer Ther; 2010 Aug; 9(8):2423-9. PubMed ID: 20682649
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
12. Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
Hall FL; Levy JP; Reed RA; Petchpud WN; Chua VS; Chawla SP; Gordon EM
Oncol Rep; 2010 Oct; 24(4):829-33. PubMed ID: 20811660
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Ikeda M; Sato A; Mochizuki N; Toyosaki K; Miyoshi C; Fujioka R; Mitsunaga S; Ohno I; Hashimoto Y; Takahashi H; Hasegawa H; Nomura S; Takahashi R; Yomoda S; Tsuchihara K; Kishino S; Esumi H
Cancer Sci; 2016 Dec; 107(12):1818-1824. PubMed ID: 27685612
[TBL] [Abstract][Full Text] [Related]
14. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
[TBL] [Abstract][Full Text] [Related]
16. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Zhen DB; Griffith KA; Ruch JM; Camphausen K; Savage JE; Kim EJ; Sahai V; Simeone DM; Zalupski MM
Invest New Drugs; 2016 Dec; 34(6):733-739. PubMed ID: 27439894
[TBL] [Abstract][Full Text] [Related]
18. Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.
Ziske C; Nagaraj S; Märten A; Gorschlüter M; Strehl J; Sauerbruch T; Abraham NG; Schmidt-Wolf IG
J Interferon Cytokine Res; 2004 Aug; 24(8):490-6. PubMed ID: 15320962
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
